AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is currently conducting a national multicenter non-interventional study titled ‘CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia.’ The study aims to assess diagnostic and treatment approaches for patients with unresectable locally advanced non-small cell lung cancer (LA NSCLC) and limited-stage small cell lung carcinoma (LS-SCLC) across 50 major oncology centers in Russia. This research is significant as it seeks to understand real-world practices and outcomes in treating these conditions.
The study focuses on chemo-radiation therapy (CRT) as the intervention, which is a combination of chemotherapy and radiation therapy used to treat cancer. The purpose is to evaluate routine diagnostic procedures and treatment outcomes without collecting data on specific treatments following CRT.
This observational study uses a cohort model with a prospective time perspective. It involves secondary data collection from existing medical records of 2000 patients, ensuring compliance with local regulatory requirements for adverse event reporting.
The study began on March 31, 2023, and aims to complete primary data collection within two years. The latest update was submitted on August 11, 2025, indicating ongoing progress.
This update could influence AstraZeneca’s stock performance by showcasing their commitment to understanding and improving cancer treatment practices, potentially boosting investor confidence. In the competitive oncology market, such studies are crucial for maintaining a leading position.
The study is ongoing, with further details available on the ClinicalTrials portal.